Indefinite Delivery Contract HQ085926DG036

The DNA Medicine Institute, Inc. has been awarded a Multiple Award Indefinite Delivery Indefinite Quantity (IDIQ) contract by the Missile Defense Agency with a ceiling value of $151 billion and a period of performance extending through December 28, 2035. This contract, awarded on December 29, 2025, with no set-aside designation, represents a broad-based contracting vehicle designed to support the Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) program. The initial delivery order, valued at $500 and issued on the same date as the IDV award, is titled "SHIELD Initial Order" and is performance-based in Huntsville, Alabama. The contract employs a firm fixed price pricing structure for individual task orders and utilizes full and open competition across multiple award recipients.

Under this IDIQ vehicle, The DNA Medicine Institute will support the Missile Defense Agency's mission to procure advanced, multi-domain defense systems capable of detecting, tracking, intercepting, and neutralizing threats to United States homeland, deployed forces, allies, and friends. The work encompasses research and development, prototyping, disruptive technologies, systems engineering, weapon design, production, test and evaluation, cybersecurity, and modernization efforts against air, missile, space, cyber, and hybrid threats across all phases of flight from ballistic, hypersonic, and cruise missiles. The contract is structured to support both classified and unclassified programs across multiple security domains and leverages advanced technologies including artificial intelligence, machine learning, digital engineering, and open systems architectures. As a multiple award IDIQ with anticipated individual task orders across various contract types and NAICS codes, the vehicle provides the Missile Defense Agency and other Department of Defense entities with flexible, rapid ordering mechanisms to address critical homeland defense requirements over the ten-year contract period.